The European Medicines Agency has rejected 76% of the proposals by pharmaceutical companies to redact what they claimed was commercially confidential information (CCI) in their clinical study reports under the agency's landmark policy on the proactive publication of clinical trial data.
The most common reason for these rejections was that either the information was already available in the public domain or...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?